ASCO 2022 | Overall survival by IDH2 mutant allele in late-stage R/R AML patients enrolled in IDHENTIFY
Stéphane de Botton, MD, PhD, Gustave Roussy Institute, Paris, France, discusses a subgroup analysis of the IDHENTIFY study (NCT02577406) where overall survival (OS) by IDH2 mutant allele in patients with late-stage mutant IDH2 relapsed/refractory (R/R) acute myeloid leukemia (AML) is evaluated. IDHENTIFY is a Phase III study investigating enasidenib compared to conventional care regimens in R/R AML. In this update, mutational burden and co-mutational profiles differed between patients with mIDH2-R140 and mIDH2-R172 R/R AML. Enasidenib improved survival outcomes for patients with IDH2-R172 mutations, with median OS and 1-year survival rate approximately double those in the standard of care arm. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
